Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 14/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.68 |
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | NPC1 | O15118 | 9/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.68 |
| ▸ | POLB | P06746 | 9/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.68 |
| ▸ | RECQL | P46063 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756723 | 0.90 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12756716 | 0.90 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1892078 | 0.81 | KMT2A (1.00) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1892079 | 0.81 | KMT2A (1.00) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12830157 | 0.75 | MAPT (0.62) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6848556 | 0.74 | RAB9A (0.74) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12830151 | 0.73 | TRPA1 (0.56) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12830153 | 0.73 | TRPA1 (0.56) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1490816 | 0.72 | MAPT (0.58) | MEN1KMT2ARAB9ANPC1L3MBTL1 | |
| SCHEMBL6541745 | 0.72 | KMT2A (0.74) | MEN1KMT2ASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MEN1 2958/4885KMT2A 4706/4885SMN1; SMN2 854/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MEN1 2958/4885KMT2A 4706/4885SMN1; SMN2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.